Diabetes mellitus (DM) is a metabolic disease, and diabetes patients have long-term higher blood sugar levels than standard. Most people with diabetes have complications that greatly affect their standard of living. Patients with type 2 DM occupy the vast majority of all diabetes patients. Glucagonlike peptide-1 (GLP-1) secreted by intestinal enteroendocrine L-cells is a small molecule polypeptide, which is glucose concentration-dependent and can effectively reduce blood glucose concentration. Dipeptidyl peptidase-4 (DPP-4) is an important target for the treatment of type 2 DM because it can degrade GLP-1. DPP-4 inhibitors can enhance the blood glucose lowering effect of GLP-1 by inhibiting DPP-4. This article summarizes the development of DPP-4 inhibitors from 2015 to 2019, and can provide helpful information for the discovery of novel DPP-4 inhibitors in the future.

糖尿病（DM）是一种代谢性疾病，糖尿病患者的血糖水平长期高于正常水平。大多数糖尿病患者的并发症会极大地影响他们的生活水平。2型糖尿病患者占所有糖尿病患者的绝大多数。肠肠内分泌L细胞分泌的胰高血糖素样肽1（GLP-1）是一种小分子多肽，它是葡萄糖浓度依赖性的，可以有效降低血糖浓度。二肽基肽酶-4（DPP-4）是治疗2型DM的重要靶标，因为它可以降解GLP-1。DPP-4抑制剂可通过抑制DPP-4来增强GLP-1的降血糖作用。本文概述了DPP-4抑制剂从2015年到2019年的发展，